<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338949</url>
  </required_header>
  <id_info>
    <org_study_id>K23MH074540</org_study_id>
    <secondary_id>K23MH074540</secondary_id>
    <secondary_id>GA128029</secondary_id>
    <nct_id>NCT00338949</nct_id>
  </id_info>
  <brief_title>Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes</brief_title>
  <official_title>The Metabolic Syndrome in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veterans Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Veterans Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a&#xD;
      standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess&#xD;
      abdominal fat storage in people with schizophrenia who are at risk for diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People with schizophrenia often lead more sedentary lifestyles than people without the&#xD;
      disease, and they are frequently treated with antipsychotic medications that cause weight&#xD;
      gain. Combined, these factors produce an increased risk for metabolic syndrome, which can&#xD;
      lead to heart disease and type 2 diabetes. Characteristics of metabolic syndrome include&#xD;
      carrying excess weight around the abdominal region; high blood pressure; high blood sugar&#xD;
      levels; high levels of fat in the blood; and low levels of HDL cholesterol. Recent studies&#xD;
      have shown that certain atypical antipsychotic drugs are relatively weight-neutral. Switching&#xD;
      from a drug that promotes weight gain to a weight-neutral medication, such as ziprasidone,&#xD;
      may result in significant weight loss. There is insufficient evidence, however, demonstrating&#xD;
      the extent of improvement in insulin sensitivity after switching medications. This study will&#xD;
      evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical&#xD;
      antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage&#xD;
      in people with schizophrenia who are at risk for diabetes.&#xD;
&#xD;
      Participants in this open label study will currently be undergoing treatment with risperidone&#xD;
      or olanzapine at the time of study entry. Upon study entry, they will be randomly assigned to&#xD;
      either switch to ziprasidone treatment or remain on their current medications. Both groups&#xD;
      will be treated for 26 weeks. Participants will report to the study site for evaluations&#xD;
      biweekly until week 10 and then monthly for the duration of the study. The primary outcomes&#xD;
      at Week 26 will be: change from baseline in insulin sensitivity, using an intravenous glucose&#xD;
      tolerance test; change from baseline in ivisceral fat mass, using a CT scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity Index From Baseline to Week 26 ((1/mU/L) x 1/Min)</measure>
    <time_frame>Measured at Baseline and Week 26</time_frame>
    <description>As measured by frequently sampled intravenous glucose tolerance testing (units: 1/mU/L) x 1/Min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visceral Fat Mass From Baseline to Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>CT measured change in visceral fat mass from baseline to week 26 (mm^3)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Metabolic Syndrome X</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants on risperidone or olanzapine who will remain on risperidone or olanzapine and do not switch to ziprasidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who enter on risperidone or olanzapine and switch to ziprasidone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch</intervention_name>
    <description>Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.</description>
    <arm_group_label>Switch</arm_group_label>
    <other_name>ziprasidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>risperidone</other_name>
    <other_name>olanzapine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of schizophrenia or schizoaffective disorder&#xD;
&#xD;
          -  Currently receiving antipsychotic therapy with risperidone or olanzapine&#xD;
&#xD;
          -  Overweight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of diabetes&#xD;
&#xD;
          -  Hospitalization for schizophrenia or schizoaffective disorder within 90 days prior to&#xD;
             study entry&#xD;
&#xD;
          -  Refractory schizophrenia or schizoaffective disorder&#xD;
&#xD;
          -  Currently receiving therapy with clozapine&#xD;
&#xD;
          -  No stable residence and phone number for 90 days prior to study entry&#xD;
&#xD;
          -  Prior unsuccessful treatment with ziprasidone&#xD;
&#xD;
          -  Intolerance to ziprasidone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan M. Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego &amp; VA San Diego Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005 Dec 1;80(1):19-32. Epub 2005 Aug 30.</citation>
    <PMID>16137860</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 16, 2006</study_first_submitted>
  <study_first_submitted_qc>June 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <results_first_submitted>May 17, 2016</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2020</results_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Veterans Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Jonathan M. Meyer, MD</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Ziprasidone</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Insulin Sensitivity</keyword>
  <keyword>Visceral Adiposity</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started 06/01/2006. Eligibility: nondiabetic, overweight/obese psychiatrically stable adult outpatients in San Diego with schizophrenia/schizoaffective disorder, on risperidone or olanzapine. Recruitment ended: 12/31/2009</recruitment_details>
      <pre_assignment_details>Exclusions: unstable housing, psychiatric hospitalization in the past 90 days, ongoing substance abuse (except nicotine), history of diabetes mellitus, pregnancy, refractory schizophrenia, prior failure of or intolerance to ziprasidone, oral glucose tolerance test indicative of diabetes mellitus, or corrected QT interval ≥ 500 msec on EKG.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Remain on risperidone or olanzapine.</description>
        </group>
        <group group_id="P2">
          <title>Switch</title>
          <description>Switch from risperidone or olanzapine to ziprasidone. Ziprasidone will be flexibly dosed based on tolerability and psychiatric response (max dose 200 PO mg/d with food).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Subject Screening</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failures</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24">1 subject withdrew after relapse and hospitalization</participants>
                <participants group_id="P2" count="25">Reasons for drop out:&#xD;
2- insomnia 2- symptom exacerbation&#xD;
1- akathisia</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Nondiabetic, overweight/obese psychiatrically stable adult outpatients with schizophrenia or schizoaffective disorder, on risperidone or olanzapine.</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Remain on risperidone or olanzapine.</description>
        </group>
        <group group_id="B2">
          <title>Switch</title>
          <description>Switch from risperidone or olanzapine to ziprasidone. Ziprasidone will be flexibly dosed based on tolerability and psychiatric response (max dose 200 PO mg/d with food).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.15" spread="8.15"/>
                    <measurement group_id="B2" value="48.73" spread="8.42"/>
                    <measurement group_id="B3" value="48.00" spread="8.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family Diabetes Mellitus History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Family Hx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Family Hx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonsmoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.52" spread="4.49"/>
                    <measurement group_id="B2" value="34.64" spread="7.60"/>
                    <measurement group_id="B3" value="33.68" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Antipsychotic</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Risperidone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olanzapine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PANSS Total Score</title>
          <description>Positive and Negative Syndrome Scale Total Score, summed from the positive, negative and general psychopathology subscales. Range 30-210, with higher scores indicating greater psychopathology.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.72" spread="11.70"/>
                    <measurement group_id="B2" value="65.20" spread="10.66"/>
                    <measurement group_id="B3" value="64.07" spread="11.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central visceral fat volume by CT</title>
          <description>Calculated from CT imaging in units of cubic millimeters (mm^3).</description>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28442" spread="10634"/>
                    <measurement group_id="B2" value="26939" spread="12060"/>
                    <measurement group_id="B3" value="27622" spread="11412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin sensitivity index</title>
          <description>Calculated in units of [(1/(mU/L) x 1/min)]</description>
          <units>(1/mU/L) x 1/Min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.596" spread="1.00"/>
                    <measurement group_id="B2" value="1.504" spread="0.902"/>
                    <measurement group_id="B3" value="1.55" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Sensitivity Index From Baseline to Week 26 ((1/mU/L) x 1/Min)</title>
        <description>As measured by frequently sampled intravenous glucose tolerance testing (units: 1/mU/L) x 1/Min)</description>
        <time_frame>Measured at Baseline and Week 26</time_frame>
        <population>Completers</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Remain on risperidone or olanzapine.</description>
          </group>
          <group group_id="O2">
            <title>Switch</title>
            <description>Switch from risperidone or olanzapine to ziprasidone. Ziprasidone will be flexibly dosed based on tolerability and psychiatric response (max dose 200 PO mg/d with food).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity Index From Baseline to Week 26 ((1/mU/L) x 1/Min)</title>
          <description>As measured by frequently sampled intravenous glucose tolerance testing (units: 1/mU/L) x 1/Min)</description>
          <population>Completers</population>
          <units>(1/mU/L) x 1/Min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.072" spread="0.955"/>
                    <measurement group_id="O2" value="0.407" spread="0.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.228</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Visceral Fat Mass From Baseline to Week 26</title>
        <description>CT measured change in visceral fat mass from baseline to week 26 (mm^3)</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Completers</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Remain on risperidone or olanzapine.</description>
          </group>
          <group group_id="O2">
            <title>Switch</title>
            <description>Switch from risperidone or olanzapine to ziprasidone. Ziprasidone will be flexibly dosed based on tolerability and psychiatric response (max dose 200 PO mg/d with food).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visceral Fat Mass From Baseline to Week 26</title>
          <description>CT measured change in visceral fat mass from baseline to week 26 (mm^3)</description>
          <population>Completers</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315" spread="5693"/>
                    <measurement group_id="O2" value="392" spread="4340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.958</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Remain on risperidone or olanzapine.</description>
        </group>
        <group group_id="E2">
          <title>Switch</title>
          <description>Switch from risperidone or olanzapine to ziprasidone. Ziprasidone will be flexibly dosed based on tolerability and psychiatric response (max dose 200 PO mg/d with food).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED-CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED-CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Barnes Akathisia Scale</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open label, stable patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jonathan Meyer MD</name_or_title>
      <organization>UCSD/VA San Diego</organization>
      <phone>8589640777</phone>
      <email>jmmeyer@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

